I	medRxiv preprint doi: https://doi.org/10.1101/2023.12.05.23299517; this version posted December 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
1	It is made available under a CC-BY 4.0 International license . Full Title
2	Impact of a pilot mHealth intervention on treatment outcomes of TB patients seeking care in the private sector
2	using Droponsity Scores Matching - Evidence collated from New Delhi India
5	using Propensity Scores Matching – Evidence conated from New Deini, India
4	Snort litle
5	mHealth intervention and treatment outcomes of TB patients
6	
7	Authors : Ridhima Sodhi ^{1¶*} , Vindhya Vatsyayan ^{1¶} , Vikas Panibatla ^{2&} , Khasim Sayyad ^{2&} , Jason Williams ^{3&} , Theresa
8	Pattery ^{3&} , Arnab Pal ^{1&}
9	1. William J Clinton Foundation, New Delhi, India
10	2. TB Alert India, New Delhi, India
11	3. Disease Management Programs, Global Public Health at Johnson & Johnson
12	
13	* Corresponding author
14	E-mail: <u>ridhimasodhi@gmail.com</u> (RS)
15	
16	¶These authors contributed equally to this work
17	&These authors also contributed equally to this work
18	
19	
20	
21	
22	
23	
24	
25	
25	
20	
27	
28	
29	
30	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 Abstract

32 Mobile health applications called Digital Adherence Technologies (DATs) are increasingly used for improving 33 treatment adherence among Tuberculosis patients to attain cure, and/or other chronic diseases requiring long term 34 and complex medication regimens. These DATs are found to be useful in resource limited settings because of their 35 cost efficiency in reaching out to vulnerable groups (providing pill & clinic visit reminders, health information and 36 awareness on the disease along with motivational messages and support to be retained in care) or those staying in 37 remote or rural areas. Despite their growing ubiquity, there is very limited evidence on how they improve healthcare 38 outcomes. We analyze the uptake of such an intervention in an urban setting (DS-DOST, powered by Connect for 39 LifeTM, Johnson & Johnson) among different patient groups accessing TB services in New Delhi, India, and 40 subsequently assess its impact in improving patient engagement and treatment outcomes. This study aims to 41 understand the uptake patterns of a digital adherence technology and its impact in improving follow ups and treatment 42 outcomes among TB patients. Propensity choice modelling was used to create balanced treated and untreated patient 43 datasets, before applying simple ordinary least square and logistic regression methods to estimate the causal impact of 44 the intervention on the number of follow ups made with the patient and treatment outcomes.

45

46 After controlling for potential confounders, it is found that patients who installed and utilized DS-DOST

47 application received an average of 6.4 (95% C.I. [5.32 to 7.557]) additional follow-ups, relative to those who did not

48 utilize the application. This translates to a 58% increase. They also had 245% higher likelihood of a treatment

49 success (Odds ratio: 3.458; 95% C.I. [1.709 to 6.996]). Descriptive results indicate that young females, and those

50 suffering from pulmonary tuberculosis have a slightly higher propensity to use the CfLTM app, and benefit through

51 their treatment duration.

52 Author Summary

53 The research tries to understand the impact of using cost-effective digital adherence tools, in improving treatment 54 outcomes among patients diagnosed with drug-sensitive Tuberculosis (TB). As the treatment duration for TB is fairly 55 long (at least 6 months) and complicated (multiple drugs, typically given in two distinct phases), there are challenges 56 associated with ensuring treatment adherence. The research finds that digital tools such as a mobile application - can 57 be a useful aid, albeit only when they are used in conjunction with the support of a healthcare worker. The digital tool 58 analyzed, while sending medication reminders to patients, also enabled healthcare workers in tracking adherence for 59 their assigned patients. The latter, as the research finds, ensured that they follow up with their patients to ensure 60 adherence, resulting in increased odds of their getting a favourable treatment outcome. Further, the study underscores 61 that a digital intervention used in isolation might not draw a favourable impact among patients - highlighting the role

62 of healthcare workers and tailored interventions. In conclusion, digital adherence technologies can act as cost-effective

63 measures in empowering healthcare workers to support their patients, and subsequently improve treatment outcomes.

64

Introduction/Background 65

Digital adherence technologies (DATs) have increasingly evolved over time, and yet, evidence evaluating their 66 67 impact on intended treatment or patient management outcomes is limited [1]–[3]. A previous study outlines multiple approaches of evidence generation for evaluating the efficacy of a mHealth solution, while also 68 69 highlighting the inherent challenges associated [4]. One critical challenge highlighted here is the rapid pace of 70 development of technologies, which could potentially entail the developers to improve or modify the 71 intervention, thus making it difficult to accurately assess the impact of the mHealth intervention. Of the 72 multiple approaches suggested to evaluate interventions, RCTs or randomized controlled evaluations were 73 deemed to be the most common but far too long [5-7 years] in typical scenarios [4]. Another recommended approach called CEEBIT (Continuous Evaluation of Evolving Behavioural Interventions) discussed assessing 74 75 multiple technologies, while continually removing inferior technologies from the competitive race [4], [5]. 76 77 Notwithstanding the challenges, multiple studies have emphasized a need for evaluating DATs, and a 78 simultaneous lack of the same [2], [6]–[8]. A systematic evaluation evaluating the role of mobile health 79 interventions in enhancing interventions PPM (public- private mix) for TB care illustrated the increasing 80 universe of such solutions [9]. However, none of the studies were found to evaluate the precise impact of such 81 technologies on patient management (encompassing one or all aspects of pill reminders, patient follow ups, 82 monitoring adherence, empowering patients with messages on disease awareness, side effects and health 83 information) along with treatment outcomes. Even in more general studies documenting the usage of such 84 technologies in TB care, there is a lack of quantitative evidence detailing the precise impact of such 85 technologies on improving disease management or behaviour modification [1], [2].

86

87 Our study is aimed at closing this gap, by assessing the impact of a pilot intervention with Connect for 88 Life[™](CfL), a mobile-based digital adherence technology on patient management and treatment outcomes. 89 The study utilizes propensity choice modelling to balance the test and control group, thus enabling precise 90 estimates of the impact on treatment outcomes. The natural limitation of this method is that the test and 91 control groups can only be balanced for the covariates on which the data is available. However, the magnitude

92 and significance of results obtained, across different model specifications, render confidence to the inferences

93 gathered.

94 **Methods**

Ethical Approval 95

96 CHAI's Scientific and Ethical Review Committee (SERC) waived informed consent as anonymized

- 97 programmatic data was utilized for the study. Additionally, all the individuals who enrolled in the CfL
- pilot did give an informed consent prior to enrolment in the pilot, through a written statement, and 98
- 99 also gave consent via IVRS. In case of patients who were below 18 years of age, parents/guardians
- 100 were primary participants, who provided written consent.

101 **DS-TB care services under Project JEET**

The Joint Effort for Elimination of Tuberculosis (Project JEET) began in 2018 and is a large-scale private health 102 103 sector engagement initiative for TB [10]. The services offered through the program are intended to reduce 104 challenges which limit the Indian healthcare system in arresting TB transmission, facilitating access to 105 appropriate TB care, and supporting TB patients throughout their treatment. As part of JEET, treatment 106 coordinators facilitate the notification of newly diagnosed TB patients in a digital government tracking system 107 called Nikshay, by liaising with private providers. This notification helps in tracking diagnosed patients and 108 offering them a package of services provided by the National Tuberculosis Elimination program (NTEP). The 109 patients also get regular counselling support by a designated treatment coordinator by way of in-person and 110 telephonic follow ups, along with quality assured diagnostic services (Xpert Testing) and access to free 111 government sponsored FDC (Fixed Dose Combination) drugs. The services are provided in close coordination 112 with the treating physician, and as deemed appropriate by them. The program helps in limiting the onward 113 transmission of disease through the combination of support described. At the time of initiation of the CfL pilot 114 (November 2019), approximately 900 private providers in New Delhi were engaged with Project JEET as part of 115 the Patient Provider Support Agency (PPSA) managed by the William J. Clinton Foundation (WJCF).

116 Pilot Set up

The pilot was initiated in the month of November 2019, in three private care facilities in New Delhi, India, 117

118 namely, Vinod Karhana Hospital, Ganga Ram Hospital, and St. Stephens hospital. The patients under this

119 intervention were notified through Project JEET. The intervention was done in collaboration between William J medRxiv preprint doi: https://doi.org/10.1101/2023.12.05.23299517; this version posted December 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license . Clinton Foundation (WJCF), TB Alert, India & Johnson & Johnson (J&J), wherein the latter developed and 120 customized Connect for Life[™], a mobile application built to help treatment providers and healthcare workers 121 in patient management. The digital intervention was voluntary in nature, wherein newly diagnosed TB patients 122 123 (or/and their caregivers) were informed about the CfL application and were asked for consent to being a part 124 of this program. New patients were enrolled in the pilot between 26th November 2019 and 15th March 2020. 125 Patients who consented were provided with digital support offered by the CfL mobile application and a 126 designated treatment coordinator, in addition to the standard services provided to patients managed under 127 Project JEET. Two key elements of the pilot are described below: 128 1) **Connect for Life™**: This is a mobile, feature or smartphone-based health application system which 129 utilizes a combination of IVRS (Interactive Voice Response System) and SMS (short messaging service) 130 to help patients in remembering to take their medications, provide reminders for visiting the clinic for 131 planned check-ups and medication refills, while also giving them health tips covering topics such as 132 nutrition, significance of adherence, stigma, and community transmission. As of 2021, CfL is an Open-Source Platform [11] and can be downloaded and used by any organization or country. Some key 133 134 features of the mHealth application include:

- 135 a) Facility to enrol both the patient and the caregiver
- b) The user could modify the frequency of the pill/health-tip reminders between 136 137 daily/weekly/monthly, and could also set up a preferred time during the day for receiving reminders 138
- 139 c) The adherence captured through the application were pulled in a dashboard, which could then 140 be viewed by the treatment coordinator. This allowed the treatment coordinator to monitor 141 patient's adherence and follow up as needed
- 142 d) Option to opt out of service at any time during the treatment
- 143
- 2) Treatment Coordinators: Three healthcare workers were engaged for the pilot, each one responsible 144 145 for patient management of the enrolled patients in one of the three private facilities. While all patients 146 under Project JEET are assigned a treatment coordinator, these three treatment coordinators were also 147 given training on how to use the mobile application and explain its functions and utilities to the 148 patients/caregivers. Once patients consented to participate in the pilot, the treatment coordinator 149 helped patients by activating their mobile telephone number with a unique password and explained 150 how to use the phone and/or text messaging functionalities. A key differentiator of these treatment

- 151 coordinators was that they had access to the CfL visualization dashboard, which enabled them to 152 monitor the self-recorded medication adherence by patients using the application. This helped them in providing differentiated counselling to the patients, by optimizing the counselling and follow-ups based 153 154 on the analytics provided by the dashboard. This potentially helped reduce the burden of patient 155 management for the treatment coordinators. Training of the treatment coordinators: The three treatment coordinators engaged for the pilot were 156 157 trained by the WJCF staff. They worked very similar to the treatment coordinators working under 158 Project JEET, following the same counselling guides and protocols. Like other treatment coordinators 159 (which are not employed specifically for this intervention), they were also responsible for updating 160 patient's demographic and treatment information in Nikshay.

Study design 161

The guasi-experimental study compared the follow up regimen and treatment outcomes of patients who were 162

163 part of the CfL pilot (test dataset), with patients who were not part of the pilot, but were notified during the

164 same time period in the same three facilities (control dataset). Both test & control datasets were matched

165 using propensity scores for ensuring robust measures.

166 Data source(s)

167 There are two data sources utilized for this study. The first is data obtained from the CfL application, which 168 consisted of information on 476 patients who were signed up for the pilot. The other source is programmatic 169 data collected as part of the services rendered under Project JEET. The data collected as part of regular JEET 170 operations included 1) TB patients demographic characteristics such as age, sex, and diagnosing district, 2) TB 171 diagnostic and treatment information, including type of diagnostic test performed, pulmonary or 172 extrapulmonary diagnosis, whether free drugs were provided, patients' treatment outcome, and 3) number of 173 follow-up contacts made by treatment coordinators. The data collected by the pilot intervention included 174 information on utilization of the CfL application. This consisted of multiple metrics such as the preferable time 175 for health tips delivery for each patient, whether or not they recorded the adherence, and the number of 176 times they interacted with the IVRS for various services. It also had information on which of the 476 patients 177 provided consent (or not) and if a patient stayed engaged with the CfL pilot through the course of their 178 treatment.

Data Selection (Inclusion & Exclusion criteria) 179

180	We considered data for patients that were enrolled in one of the three facilities where the pilot was conducted
181	and were diagnosed of drug sensitive TB between 1 st October 2019 and 31 st March 2020. This also represents
182	patients who were diagnosed before the COVID-19 pandemic started impacting health services operations in
183	India (the first nation-wide lockdown in India was implemented on 24 th of March 2020). Among these, only those
184	patients were considered who had had a treatment outcome assigned to them at the time this study was
185	conducted. The selection criteria are described in more detail in Table 1 & 2. A total of 989 patients were
186	enrolled, of which 276 enrolled in the CfL application, provided consent and utilized it through their treatment.
187	

188

189 Table 1

190 CfL Test dataset: Selection criteria pathway

Beason for inclusion/exclusion	#Patients	Patients	
	Excluded	retained	
Patients enrolled	(+) 476	476	
Consent required	(-) 138	338	
Patients opted out of the application after using	(-) 18	320	
Patient died before treatment initiation	(-) 1	319	
Patients transferred/migrated to a different facility	(-) 35	284	
Treatment outcome is pending	(-) 7	277	
Treatment outcome should be one of cured, complete, death or treatment		276	
failure	(-) 1	276	

- 191
- 192
- 193 Table 2

194 Control dataset: Selection criteria pathway

Reason for inclusion/exclusion	#Patients	Patients
	Excluded	retained
Patients notified in New Delhi between October 2019 and March 2020		9478
Patients who were engaged with the CfL application	(-) 333	9145
Patients notified at one of the 3 facilities	(-) 8407	738
Treatment outcome is pending	(-) 13	725

medRxiv preprint doi: https://doi.org/10.1101/2023.12.05.23299517; this version posted December 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Treatment outcome should be one of cured, complete, death or treatment (-) 12 713

195

Model Theory

197 We fit multiple statistical models to understand how the CfL engagement impacted patients and their

failure

- 198 treatment outcomes. Our findings suggest that the combination of features provided by the CfL application
- 199 contributed to the patient being more engaged with their treatment. Routine health tips, along with
- 200 medication reminders, customized to be received at a chosen time of patient's preference helped prevent
- 201 challenges to continued treatment adherence, and encouraged the patient to stay connected with their
- 202 treatment coordinator. Simultaneously, treatment coordinators utilized the platform to monitor patients'
- adherence, and increased follow ups if and when the patients were found to lag behind in medication
- adherence. These factors then contribute to better treatment adherence, leading to better treatment
- 205 outcomes (Figure 1). The study attempts to develop a precise estimate of the treatment effect of CfL on
- 206 patients' follow-ups and treatment outcome by using a combination of regression methods on a matched
- 207 dataset built through propensity choice modelling.
- 208



209

210 **Outcomes of Interest**

The study has two primary outcomes, 1) patient follow-ups and 2) treatment outcomes. Patient follow ups refers to the number of times a patient spoke to or met with a treatment coordinator, and acts as a proxy for patient management. Treatment outcomes are analyzed as a binary variable in the study. Five outcomes are considered

1) treatment complete, 2) cured, 3) treatment failure, 4) death, or 5) lost to follow-up. The first two correspond

to a successful outcome, and the last three correspond to an unsuccessful one. These outcomes are further

216 described with clinical definitions in Appendix 1 [12].

217 Propensity Choice Modelling

Effectively, all diagnosed TB patients who visited the three facilities during the pilot initiation were offered to 218 219 enrol for the CfL intervention, meaning the data collected as part of this study was not randomized. This makes 220 it difficult to access the average treatment effect (ATE) of the intervention on the outcomes of interest. While 221 randomized experiments are a preferred choice to understand the causal effect of a treatment, running such an 222 experiment is often cost intensive and consists of multiple ethical issues (primarily with respect to who receives 223 the intervention), especially in studies concerning welfare and healthcare treatment effects [13]. Several studies 224 have acknowledged the usage of matching methods to infer causal insights from observational data, specifically 225 in the field of health care assessment [14], [15]. It is documented that creating a dataset which is matched on 226 choice attributes provides an opportunity to estimate the average effect of the treatment as if it were a randomized experiment, which means if the access to CfL was randomly assigned to individual patients [16]. 227

We utilized propensity score modelling to create a matched dataset comprised of treated patients (enrolled in the CfL) and untreated patients (not enrolled), which also included data on potential confounders for each individual [14], [17]–[20]. The propensity score refers to the conditional probability of a patient being enrolled in the pilot, given the values of all potential confounder [18]. This score was estimated for each patient in the full analytical dataset. These scores were then used to create comparable groups of people who were part of the pilot engagement (treated) and those who did not ever engage (untreated). The scores were adequate predictors of whether or not a patient enrolled in the pilot, illustrated in Appendix 2 (Figure SF1, Table S2, S3).

235 We identified pairs of observations that have very similar propensity scores, but that differed in their treatment status (CfL or not), and employed the full matching algorithm, first developed by Rosenbaum (1991) [21] and 236 237 illustrated by Hansen (2004) [22]. It uses all available individuals in the data by grouping the individuals into a 238 series of matched sets (subclasses), with each matched set containing at least 1 treated individual (who received the treatment of interest) and at least 1 comparison individual (who did not). Full matching forms these matched 239 240 sets in an optimal way, such that treated individuals who have many comparison individuals who are similar (on 241 the basis of the propensity score) will be grouped with many comparison individuals, whereas treated individuals 242 with few similar comparison individuals will be grouped with relatively fewer comparison individuals. The 243 method is thus more flexible than traditional k:1 matching, in which each treated individual is required to be

matched with the same number of comparison individuals (k), regardless of whether each individual actually has k good matches [23]. To counter any bias, we adopted two measures. First, we employed a calliper width of 0.2 for the age and district variables using nearest neighbour matching, meaning the matched pairs were a maximum of 0.2 standard deviations away from each other, which is described as ideal by previous studies [24]. Second, we employed exact matching on four variables: 1) proportion of males, 2) proportion of extra pulmonary

- cases, 3) proportion of patients diagnosed using Xpert testing, and 4) access to free drugs.

250 Statistical modelling

- 251 Using the matched dataset, we fit fixed-effects ordinary least squares (OLS) regression and fixed-effects logistic
- 252 regression models to estimate the impact of CfL engagement on the number of follow-ups made with the
- 253 patient and the likelihood of a successful treatment outcome, respectively. As covariates in the OLS regression
- 254 model, we fitted a series of models, sequentially including CfL engagement, diagnosing facility, sex, age
- category (0 to 5, 6 to 15, 16 to 19, 20 to 45, 46 to 65, and \geq 66 years), TB type (pulmonary or extra pulmonary),
- whether Xpert diagnostics were used, access to free drugs, and the quarter in which the diagnosis was made.
- 257 The logistic regression model was fit to assess the likelihood of a patient receiving a successful outcome at the
- 258 culmination of treatment. The same covariates went into the logistic regression model.
- 259 Diagnosing quarter was included in the model OLS and logistic regression models to control for seasonal
- 260 program-related influences of patient care and adherence to treatment. Interaction effects on diagnosing
- 261 facility and diagnosing quarter were considered in both models to account for the simultaneous effect of these
- two variables on the dependent variables [25].
- 263 To establish the linkage between follow ups and treatment outcomes, a logistic model was fit with follow ups
- as an additional dependent variable, while including for the status of CfL engagement and other covariates.

265 Sensitivity Analysis

Multiple sensitivity analyses were conducted to understand the impact of the CfL engagement on follow ups and treatment outcomes. These are illustrated in the forest plots (Figures 6 and 7), tabular results of which are provided in Appendix 5. Our results were robust to specifications which excluded cases where treatment outcome resulted in lost to follow up, or when we ran facility specific models. The results were also robust to alternative matching methods, wherein we utilized nearest neighbor matching, along with exact matching for selected variables (Appendix 6). The latter resulted in 204 matched pairs.

Statistical software 272

- 273 Analysis was conducted in R 2022.07.01. `MatchIt` package [26], [27] was used for the propensity score
- 274 matching procedure, 'broom', 'cobalt', and 'gtsummary' packages were used for visualizing fitted and residual
- 275 values, generating balance plots from propensity choice modelling, and generating summary statistics,
- 276 respectively. Packages used for data cleaning, preparing the analytical datasets, measuring skewness, and
- 277 visualizing results were `dplyr`, `tidyr`, `moments`, and `ggplot2`.

Results 278

- Tables 3 provides the demographic and clinical profiles of patients in the analytical dataset (989 patients) and 279
- 280 matched dataset (944 patients). Table 4 further provides this information, albeit segregated by the pilot
- 281 engagement status. The matching process using propensity scores brought the standardized propensity score
- 282 difference between the treated and control group from 0.28 to 0, while balancing the mean difference
- 283 between other covariates (Appendix 3). Within the matched dataset, 56% patients were male, 20% of patients
- were diagnosed using Xpert testing, 56% patients had extra pulmonary TB, and 88% of patients had a 284

285 successful treatment outcome recorded.

- 286
- 287

Table 3 288

289 Summary statistics for dataset before and after matching

	Analytical Dataset	Matched dataset
Number of patients	989	944
Males	554 (56%)	530 (56%)
Age Category		
1. 0-5	9 (0.9%)	9 (1.0%)
2. 6-15	67 (6.8%)	65 (6.9%)
3. 16-19	91 (9.2%)	85 (9.0%)
4. 20-45	490 (50%)	477 (50%)
5. 46-65	246 (25%)	226 (24%)
6. >65	86 (8.7%)	82 (8.7%)
Age		

medRxiv preprint doi: https://doi.org/10.1101/2023.12.0 preprint (which was not certified by peer review) is	5.23299517; this version posted December s the author/funder, who has granted medRxi	6, 2023. The copyright holder for this v a license to display the preprint in
It is made availab	perpetuity.	
Median (IQR)	35 (23, 53)	35 (23, 53)
Mean	38	38
Free drugs	117 (12%)	91 (9.6%)
Xpert Testing	221 (22%)	185 (20%)
Extra Pulmonary	545 (55%)	528 (56%)
Follow Ups	13 (6, 18)	13 (6, 18)
Median	13 (6, 18)	13 (6, 18)
Mean	12	12
Unknown	215	199
Facility		
sir ganga ram	529 (53%)	519 (55%)
st stephens	282 (29%)	256 (27%)
vinod karhana	178 (18%)	169 (18%)
Treatment Outcome		
complete	867 (88%)	829 (88%)
cured	3 (0.3%)	3 (0.3%)
died	91 (9.2%)	85 (9.0%)
failure	1 (0.1%)	1 (0.1%)
lost	27 (2.7%)	26 (2.8%)
Successful Treatment Outcome	870 (88%)	833 (88%)

Note: 1) The table showcases the numbers segregated by CfL status and within group percentages for them; 2) the p value for testing difference of means in groups with and without CfL; 3) n (%); Median (IQR) is given for continuous variables (age & follow ups)

290

291 Table 4

292 Summary statistics for dataset before and after matching; segregated by the CfL[™] pilot engagement status

	Analytical Dataset		Matched dataset			
		(N = 989)			(N = 944)	
Pilot engagement	no CfL	CfL	p- value	no CfL	CfL	p- value

medRxiv preprint doi: https://doi.org/10.1101/2023.12.05.23299517; this version posted December 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.									
	It is made available under a CC-BY 4.0 International license .								
Number of patients /13 2/6 694 250									
Males	406 (57%)	148 (54%)	0.3	398 (57%)	132 (53%)	0.2			
Age Category									
1.0-5	6 (0.8%)	3 (1.1%)		6 (0.9%)	3 (1.2%)				
2. 6-15	45 (6.3%)	22 (8.0%)		45 (6.5%)	20 (8.0%)				
3. 16-19	51 (7.2%)	40 (14%)		51 (7.3%)	34 (14%)				
4. 20-45	336 (47%)	154 (56%)		334 (48%)	143 (57%)				
5.46-65	200 (28%)	46 (17%)		186 (27%)	40 (16%)				
6. >65	75 (11%)	11 (4.0%)		72 (10%)	10 (4.0%)				
Age			<0.001			<0.001			
Median (IQR)	38 (24, 56)	30 (20, 42)		37 (24, 56)	30 (20, 42)				
Mean	40	33		40	33				
Free drugs	48 (6.7%)	69 (25%)	<0.001	41 (5.9%)	50 (20%)	<0.001			
Xpert Testing	105 (15%)	116 (42%)	<0.001	88 (13%)	97 (39%)	<0.001			
Extra Pulmonary	408 (57%)	137 (50%)	0.031	402 (58%)	126 (50%)	0.040			
Follow Ups						<0.001			
Unknown	185	30		173	26				
Median (IQR)	11 (4, 16)	18 (13, 20)	<0.001	11 (4, 16)	18 (13, 20)				
Mean	10	16		10	16				
Facility			<0.001			<0.001			
sir ganga ram	454 (64%)	75 (27%)		447 (64%)	72 (29%)				
st stephens	153 (21%)	129 (47%)		143 (21%)	113 (45%)				
vinod karhana	106 (15%)	72 (26%)		104 (15%)	65 (26%)				
Successful treatment outc	come 608(85%)	262(95%)	<0.001	595 (86%)	237 (95%)	<0.001			

Notes: 1) The table showcases the numbers segregated by CfL status, and within group percentages for them; 2) For binary/character variables, values represent the number of patients enrolled, and value in parentheses represents share or %; 3) For continuous values, the number represents the median, and the values in parentheses represents the Interquartile Range; 4) Pearson's Chi-squared test and Kruskal-Wallis rank sum test is conducted for p value

perpetuity. It is made available under a CC-BY 4.0 International license .





Note: The diamond dot represents mean, and the box boundary represents the inter-

293

294 Follow-ups with patients

295 Within the matched dataset, patients with the CfL[™] engagement received more follow-ups from treatment

296 coordinators (Mean=16.3, Median (IQR): 18 (13,20)) than patients who were not engaged with the pilot (Mean

297 = 10.3, Median (IQR): 11 (4, 16)). These are also illustrated in Figure 2 by way of a box plot distribution.

298 We fit a series of five regression models that progressively added patient-level covariates, fixed-effects for

299 facility, patient level covariates, fixed-effects for quarter of diagnosis, and an interaction between facility and

300 quarter of diagnosis (Table 6). All five models revealed statistically significant effect of the pilot engagement on

301 follow-ups, with Model E controlling for all available potential confounders and an interaction term on

302 diagnosing facility and quarter. Here, an average treatment effect (ATE) in terms of 6.4 additional follow-ups

303 (95% C.I. = 5.295 to 7.540) was found for patients enrolled in the pilot relative to those who were not. This is

304 equivalent to a 62% increase in mean follow-ups (58% increase if we compare median values).

305

306 Table 5

307 OLS regression results showing impact of the pilot CfL engagement on number of follow-ups with patients using

308 matched dataset; N = 745

	Model A	Model B	Model C	Model D	Model E
CfL Engagement	5.995	6.128	6.131	5.943	6.417
95% C.I.	(4.986, 7.003)	(5.070, 7.185)	(4.963, 7.298)	(4.768, 7.119)	(5.295, 7.540)
+ Facility fixed		Vec	Vac	Vac	Vac
effects		Yes	res	res	res

medRxiv preprint doi: https://doi.org/10.1101/2023.12.05.23299517; this version posted December 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpertuit.							
	It is made availa	ble under a CC-By	4 0 International lic	ense			
+ Additional Covar	+ Additional Covariates Yes Yes						
+ Diagnosing Quar	rter fixed effects			Yes	Yes		
+ Facility by Diagn	osing quarter						
interaction					Yes		
Observations	745	745	745	745	745		
R ²	0.150	0.154	0.176	0.180	0.216		
Adjusted R ²	0.148	0.151	0.162	0.166	0.200		
Desidual Std. Free	C C C (df - 742)	6.552 (df =	6.507 (df =	6.494 (df =	6.359 (df =		
Residual Stu. Error	0.501 (ui = 743)	741)	732)	731)	729)		
	130.748 (df = 1;	45.098 (df =	13.026 (df =	12.374 (df =	13.417 (df =		
F Statistic	743)	3; 741)	12; 732)	13; 731)	15; 729)		
	(df = 1; 745)	(df = 3; 743)	(df = 12; 734)	(df = 13; 733)	(df = 15; 731)		

Note: a) 95% C.I. based on robust standard errors; b) All models were fitted on matched dataset; c) *p<0.1; **p<0.05; ***p<0.01

309

310 *Treatment Outcomes*

311 A series of fixed-effects logistic regression models (Table 7) revealed a statistically significant greater likelihood

of a successful treatment outcome for patients who was enrolled in the CfL pilot, relative to those who were

not. Model E includes controls for all available covariates and reveals 242% higher odds (OR = 3.415; 95% C.I.

314 [1.701 to 6.857]) of a successful outcome for patients who was enrolled in the pilot relative to others.

315

316 Table 6

317 Logistic regression results showing impact of the pilot CfL engagement on treatment outcomes using matched

```
318 dataset; N = 944
```

	Model A	Model B	Model C	Model D	Model E
CfL Engagement	3.033***	4.631***	3.54***	3.589***	3.415***
95% C.I.	(1.668,5.517)	(2.483,8.635)	(1.776,7.056)	(1.809,7.12)	(1.701,6.857)
+ Facility fixed effects		Yes	Yes	Yes	Yes
+ Additional Covariates			Yes	Yes	Yes
+ Diagnosing Quarter fixed	effects			Yes	Yes

+ Facility by Diagnosing guarter interaction

Yes Observations 944 944 944 944 944 Log Likelihood -335.455 -319.634 -288.460 -288.411 -286.184 Akaike Inf. Crit. 602.920 674.911 647.268 604.823 604.368

Note: a) 95% C.I. based on robust standard errors; b) All models were fitted on matched dataset; c) *p<0.1; **p<0.05; ***p<0.01; d) Treatment outcome is equal to success (=1) if treatment is completed or cured. Unsuccessful outcome refers to lost to follow up, death or treatment failure

319

Link between CfL, follow ups, and treatment outcomes 320

321 Including follow ups as a covariate in the logistic model reduces the size and significance of the coefficient on

322 CfL (Table 7.1). It also reveals a statistically significant coefficient on the follow ups, estimating a 24% increased

323 likelihood of a successful outcome, for every unit increase in follow ups with the patient. Results from this

324 specification (Table 7.1), along with the model revealing a significant impact of CfL drugs on follow ups (Table

6), lead us to conclude that the CfL engagement is leading to better treatment outcomes, primarily through 325

326 their impact on the number of follow ups made with the patient.

327

328 Table 6.1

- 329 Logistic regression results showing impact of CfL on treatment outcomes using matched dataset; N = 745;
- including follow ups as a covariate 330

	Model A (Odds Batio)	95% C I
	Model A (Odds Natio)	JJ/0 C.I.
CfL	0.444	(0.181, 1.088)
Follow ups	1.242***	(1.174, 1.313)
All Covariates	Yes	
Diagnosing Quarter FE	Yes	
District FE	No	
Treatment Coordinator FE	Yes	
Observations	745	
Log Likelihood	-156.047	
Akaike Inf. Crit.	346.093	



Note: 1) LTFU refers to Lost to follow up; 2) Dotted line at X = 0 helps in visualizing the sub populations which reveal a significant impact (or not) of CfL on follow ups outcomes; 3) All facility specific models are fitted on the





Note: 1) OR Ratios are displayed along with 95% C.I.; 2) Dotted line at X = 1 illustrates the sub-populations which reveal a significant impact of CfL on treatment outcomes (to the right) or not (to the left) 3) LTFU refers

339

340 **Discussion**

To our knowledge, this is the first study assessing the impact of a DAT intervention on TB patients seeking care in the Indian private sector using a quasi-experimental approach. Our findings illustrate that patients who used the CfL application had a significantly higher likelihood of completing their treatment successfully, likely caused by an increase in follow ups associated with the usage of the application. The results stay robust after

employing robust propensity score matching methods and a series of sensitivity analysis.

346

347 While digital adherence technologies (DATs) have been increasingly used for improving patient behaviours 348 across the globe, their particular usage in India has remained underutilized, in part due to a lack of proper 349 regulation and implementation [28]. Additionally, in-person or telephonic follow ups, though a gold standard 350 to improve all aspects of patient management, can be burdensome for developing countries such as India 351 because of high patient load, stagnant workforce and high number of patients living in rural and remote areas 352 [29]. A study in Uganda illustrated the role played by such DATs where face to face counselling and social 353 support is expensive because of a lack of financial resources and difficulties in transportation [30]. Wider usage 354 of digital applications has the potential to mitigate these challenges [3]. Studies have highlighted the role of 355 effective communication through mHealth technologies in India, which could bridge the gap between patient 356 and medical staff interaction [31]. Treatment for tuberculosis is particularly complex and long drawn, which 357 further intensifies the need for different novel methods to ensure patients adhere to the treatment through 358 different challenges[32]. A modelling analysis estimates that such DATs, if employed in the public sector alone, 359 can potentially reduce TB incidence by 7.3% over a course of 10 years, and by 16% if also deployed in the 360 private sector, albeit under idealized settings [33]. Another study conducted in Bengaluru, India highlighted 361 the role of an mHealth application (Kill TB) in using reminders to improve patient adherence [34].

It is made available under a CC-BY 4.0 International license . 363 Earlier examples of digital interventions to manage adherence include 99DOTS [35], Video Directly Observed

therapy (VDOT) or Video Observed therapy (VOT) and Event Monitoring device for medication support (EMM)

365 [36]. The current landscape is still an evolving one, and evolving iterations of these devices and solutions are

366 being piloted for understanding their use cases. Recent evaluations of the Medical Event Reminder Monitor

367 (MERM) box [37] and TMEAD [38], both applications of EMM, has found favourable outcomes among patients

- using these solutions, albeit stating challenges with respect to the actual usability [37]–[41].
- 369

370 Previous studies have recommended these DATs to be used to support a larger patient-management system,

371 wherein differentiated counselling or switching to DOT can be possible options in case of non-adherence [42]-

372 [44]. While all of these interventions included a dashboard solution to enable patient monitoring by healthcare

workers, most evaluative studies have not specifically evaluated the impact thereof [2], [45]. In our study, we

374 find that patients enrolled in the CfL intervention received a higher number of follow ups. Earlier studies have

highlighted the role of enabling differentiated care [46] and the importance of human-interactions in

improving success from DATs [47]–[49]. A previous systematic review talks about using such DATs to enable

differentiated care, and more intensive face-to-face engagement as and when required [3]. With a significant

amount of mixed evidence around the impact of DATs, results from this analysis suggests that digital

technologies might show little impact if used in isolation. This follows from the fact that medication non-

adherence is a complex issue with multiple contributing factors [50], [51], and a tailored intervention is

381 required to draw positive impact from any singular technological solution [3].

382 Conclusions

383 The results from this analysis are significant in illustrating the impact of the CfL solution in improving the ability 384 of healthcare workers to counsel patients effectively, while simultaneously improving a patient's engagement 385 with their treatment by providing a combination of services (health tips delivery, drug medication reminders, 386 clinic visit reminders). Digital interventions such as these serve as a low-cost method to improve patient 387 behaviours with respect to continuing treatment. They help reach out to population groups who do not have 388 easy access to a clinic, and may be living at far-off remote, rural, or hard to reach areas which make 389 transportation costs a huge barrier in accessing clinician services. They also help reduce stigma and generate 390 awareness among patients and caregivers, potentially improving patient attitudes to treatment and care. 391 Similar interventions, which help optimize patient care, could also have the potential to reduce the 392 psychological burden borne by healthcare workers in resource-constrained settings. Future scaled

perpetuity. It is made available under a CC-BY 4.0 International license .

deployments of such technologies need to consider the importance of a multi-faceted intervention, combining

the elements of technology and human-centred approach in order to improve treatment outcomes for

395 patients.

396 Limitations

Our analysis, while strongly suggesting the impact of the CfL intervention, has several limitations which 397 398 warrant further research. First, our analysis does not investigate the specific implementation challenges 399 witnessed by the program team, which would be essential to initiating a scale up of the same across a wider 400 geography or/and a greater number of facilities. Some of the impediments noted by the program staff 401 included a) disruptions in internet/telephone-network at the home location of patients, and b) patients 402 complaining about redundant or repetitive content in health tip deliveries, and c) lengthy process to record 403 their adherence into the system. It is worth noting that broadly, the CfL application was flexible to individual 404 patients' needs. For instance, a patient or caregiver could modify the frequency of their reminders, set up a 405 preferred time for the same, while also selecting the topics on which they would require nudges (pill 406 reminders, doctor visit reminders, adherence report, nutrition, and plausible side effects, among other 407 things.). Nevertheless, quickly responding to similar challenges within a built-in software solution can be 408 cumbersome, especially if deployed across a larger patient group. Notwithstanding the plausible challenges, 409 several of the commonly found difficulties with using such solutions (application crash, data recording errors, 410 erroneous or harmful information in terms of health tips) [52] were not reported from patients or the program 411 staff using this application. Second, while the results are accompanied by a facility-level sensitivity analysis, our 412 research does not attempt to find reasons for heterogeneity in results obtained or delve into the specifics of 413 implementation in these different facilities. It is worth noting that Vinod Karhana is a relatively smaller facility, 414 with respect to the number of patients catered to, when compared with Sir Ganga Ram hospital and St. 415 Stephens hospital. Both Sir Ganga Ram and St. Stephens are situated in central Delhi, making it relatively easier 416 for patients to access them by various forms of public transportation. A more detailed, and perhaps qualitative 417 narrative of how such interventions might impact patients visiting such diverse facilities is warranted. The 418 same can help inform differential enrolment and investment strategies, which can be more efficient in utilizing 419 such DATs for TB, as well as other diseases involving long and complicated treatment regimens. Third, while 420 we investigate the impact of the intervention on treatment outcomes, we do not compare the adherence 421 recorded among patients, where the latter is the primary indicator being measured by the CfL application. Our 422 reservation against measuring the adherence stems from the fact that it is self-reported by the patient and is

423 likely to have some bias. Our analysis adopted a more outcomes-based approach, by directly evaluating the 424 impact on the number of follow ups made, and the likelihood of successful treatment completions. However, 425 research assessing medication adherence could be worthwhile in understanding more specific barriers to 426 patient engagement and the successful deployment of such interventions. Fourth, we use a derived 427 dichotomous outcome variable to understand the impact of the intervention on treatment outcomes. Here, 428 unsuccessful outcomes include treatment failure, death, and lost to follow-up, and each of these outcomes 429 may have their own risk profiles. All patients who had a treatment interruption greater than one month in 430 duration are considered as being lost to follow-up. However, it cannot be determined if patients continued the 431 treatment later, and if so, whether they were able to complete the treatment with a positive outcome. Hence, 432 including lost to follow-up has the potential to bias these results. Some previous studies have not included lost 433 to follow-up in their analyses for similar reasons [53]. However, we remain conservative and followed the 434 baseline criteria of including patients who were under the active management of a treatment coordinator, and had their outcomes reported at least a month after the date of diagnosis. Additionally, in our particular 435 analysis, lost to follow-up makes up 2.7% and 2.8% of our analytical and matched datasets, respectively. 436 437 Including lost to follow-up in analysis where these cases make less than <5% of the overall population 438 generally leads to little bias [54]. Sensitivity analysis excluding patients with lost to follow up as a treatment outcome (Appendix 6) supported the primary findings with high statistical significance. Regardless, further 439 440 research is warranted to fully understand the differential risk profile of private sector TB patients, including the drivers of lost to follow-up and treatment failure. Lastly, majority of patients reported treatment completion 441 442 which was based on the provider declaring that patient need not take any more medications. Since cure rates are low due to lack of smear testing in the private sector, the metric of successful treatment completion itself 443 444 has certain limitations. 445 446 447 448

- 449
- 450
- 451
- 452
- 453

454

455 **List of abbreviations**

- 456 DAT Digital Adherence Technology
- 457 ATE Average treatment effect
- 458 CI Confidence interval
- 459 FDC Fixed dose combination
- 460 IQR Interquartile range
- 461 JEET Joint Effort for Elimination of Tuberculosis
- 462 OLS Ordinary least squares
- 463 PPSA Private Provider Support Agency
- 464 TB Tuberculosis
- 465 NTEP National Tuberculosis Elimination Program
- 466 NSP National Strategic Plan for Elimination of Tuberculosis

467

- 468 Appendix
- 469 Appendix 1 Definition of treatment outcomes
- 470

471 Table S1

472 Definitions of treatment outcomes for drug susceptible TB patients [12]

Treatment outcome	Definition	Study outcome	Considered for the study
Cured	Microbiologically confirmed TB patients at the beginning of treatment who was smear or culture negative at the end of the complete treatment	Successful	
Treatment complete	Completed treatment without evidence of failure or clinical deterioration but with no record that the smear or culture results of biological specimen in the last month of treatment was negative	treatment	Yes

	It is made available under a CC-BY 4.0 Internationa	l license .	
Lost to follow	Treatment was interrupted for one consecutive		
up	month or more	Unsuccessful	
Died	Died during the course of anti-TB treatment	treatment	
Treatment	Biological specimen is positive by smear or culture at		
failure	end of treatment		
N	Patients for whom no treatment outcome is		
Not evaluated	assigned; also includes former transfer outs		
-	A TB patient who is on first line regimen and has		
regimen	been diagnosed as having DR TB and switched to		
	drug resistant TB regimen prior to being declared as	Other outcomes	
changed	failed	(not considered)	No
Wrongly			
diagnosed	A patient who is wrongly diagnosed of TB		
Transforred	A patient who has transferred to another facility or		
Transferred	state, prior to the outcome being declared		

473 Appendix 2 – Estimating propensity scores

474 We utilized propensity score modelling [18]–[20] to create a matched dataset comprised of treated patients

475 (CfL) and untreated patients (no CfL), by means of a logistic regression model, including all available potential

476 confounders. The exact model results from the same are given in Table S4, and Table S5 displays the mean

477 propensity scores between patients who actually received CfL or not. The accuracy of the model is 7

478 77% with a specificity rate of 19%. Figure SF1 shows the distribution of propensity scores visually, segregated

479 by whether or not the patient was on the CfL program.

480

481 Table S2

482 Estimating propensity score using logistic regression; N = 989

Dependent	Variable: CfL
male	0.955 (0.622, 1.288)
Age: 6-15	0.612 (-1.036, 2.259)
Age: 16-19	0.817 (-0.794, 2.428)
Age: 20-45	0.735 (-0.817, 2.288)
Age: 46-65	0.338 (-1.248, 1.924)

medRxiv preprint doi: https://doi.org/10.1101/2023.12.05.23299517; this version posted December 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Age: > 65 0.240 (-1.466, 1.945) 2.539 (2.111, 2.968) **Xpert Testing** Free drugs 11.113 (10.594, 11.632) Extra Pulmonary status 1.027 (0.675, 1.379) Facility: St Stephens 6.075 (5.585, 6.564) Facility: Vinod Karhana 8.295 (7.795, 8.794) Diag Qtr: 2020 Q1 2.708 (2.370, 3.047) Constant 0.069 (-1.539, 1.678) Observations 989 Log Likelihood -440.605

Akaike Inf. Crit.

Note: a) 95% C.I. based on robust standard errors; b) *p<0.1; **p<0.05; ***p<0.01; c) 95% C.I.

displayed alongside results

483

484 Table S3

485 Propensity Score estimated by whether or not a patient was on CfL

enrolled in CfL	Ν	Mean score	Median score
No	713	0.20	0.12
Yes	276	0.48	0.49

907.209





488

Appendix 3 – Propensity Score Matching

Table S4

Summary of balance for the dataset, before and after matching

	Analytical Dataset				Matched Dataset					
	Means	Means	diff	Std. Mean	Var.	Means	Means	diff	Std. Mean	Var.
	Treated	Control		Diff.	Kalio	Treated	Control		Diff.	Katio
Diff	0.48	0.20	0.28	1.25	1.37	0.44	0.44	0.00	0.00	1.00
Age: 0-5	0.01	0.01	0.00	0.02		0.01	0.01	0.00	0.01	
Age: 6-15	0.08	0.06	0.02	0.06		0.08	0.06	0.02	0.09	
Age: 16-19	0.14	0.07	0.07	0.21		0.14	0.11	0.03	0.07	
Age: 20-45	0.56	0.47	0.09	0.17		0.57	0.61	-0.03	-0.07	
Age: 46-65	0.17	0.28	-0.11	-0.31		0.16	0.16	0.00	0.00	
Age: >65	0.04	0.11	-0.07	-0.33		0.04	0.06	-0.02	-0.09	
Male	0.54	0.57	-0.03	-0.07		0.53	0.53	0.00	0.00	
Xpert Testing	0.42	0.15	0.27	0.55		0.39	0.39	0.00	0.00	
Free drugs	0.25	0.07	0.18	0.42		0.20	0.20	0.00	0.00	
Facility: sir ganga ram	0.27	0.64	-0.37	-0.82		0.29	0.28	0.01	0.02	
Facility: st stephens	0.47	0.21	0.25	0.51		0.45	0.45	0.01	0.01	
Facility: vinod karhana	0.26	0.15	0.11	0.26		0.26	0.27	-0.01	-0.03	
Diag Qtr: 2019 Q4	0.36	0.52	-0.16	-0.34		0.38	0.38	0.00	-0.01	
Diag Qtr: 2020 Q1	0.64	0.48	0.16	0.34		0.62	0.62	0.00	0.01	
Extra Pulmonary	0.50	0.57	-0.08	-0.15		0.50	0.50	0.00	0.00	

medRxiv preprint doi: https://doi.org/10.1101/2023.12.05.23299517; this version posted December 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpendicular.

perpetuity. It is made available under a CC-BY 4.0 International license .



503 *Results from the full OLS model on matched dataset;* N = 747

Dependen	t Varia	ble: Foll	low Ups
----------	---------	-----------	---------

CfL	6.438*** (0.600)
Xpert Testing	-0.785 (0.762)
Free drugs	-0.972 (0.931)
Age: 6-15	-0.315 (2.291)
Age: 16-19	-0.687 (2.257)

24

per It is made available under a	CC-BY 4.0 International license .
Age: 20-45	-0.328 (2.150)
Age: 46-65	-1.786 (2.182)
Age: > 65	-3.217 (2.303)
Male	-0.375 (0.476)
Extra Pulmonary	0.861* (0.507)
Facility: st stephens	2.663*** (0.971)
Facility: vinod karhana	4.679*** (0.977)
Diag Qtr: 2020 Q1	3.988*** (0.731)
Facility: st stephens * Diag Qtr 2020 Q1	-4.597*** (1.165)
Facility: vinod karhana * Diag Qtr 2020 Q1	-6.818*** (1.239)
Constant	8.185*** (2.251)
Observations	747
R	0.217
Adjusted R	0.201
Residual Std. Error	6.352 (df = 731)
F Statistic	13.526 (df = 15; 731)

the matched dataset; d) We have only 747 observations as 199 patients did not have a recorded value for the

number of follow ups conducted

504

505 Appendix 5 – Full Model Results; Logistic Model; Matched Dataset

506

507 Table S6

508 Logistic Regression; Impact of CfL on Treatment Outcomes; N = 946

Dependent Variable: Binary Treatment Outcome (Successful=1, Unsuccessfu				
CfL	1.241*** (0.578, 1.904)			
Xpert Testing	0.393*** (-0.271, 1.057)			
Free drugs	1.604 (-0.434, 3.642)			
Age: 6-15	0.149 (-2.155, 2.453)			
Age: 16-19	2.390 (-0.523, 5.303)			
Age: 20-45	0.320 (-1.838, 2.479)			
Age: 46-65	-0.614 (-2.778, 1.551)			

mec pre	Rxiv preprint doi: https://doi.org/10.1101/2023.12.05.23299517; this version p print (which was not certified by peer review) is the author/funder, who ha	osted December 6, 2023. The copyright holder for this s granted medRxiv a license to display the preprint in					
	perpetuity. It is made available under a $CC-BY \neq 0$ international license						
Age: > 65 -1.340 (-3.536, 0.856)							
	Male	-0.508* (-0.968, -0.048)					
	Extra Pulmonary	0.192 (-0.259, 0.643)					
	Facility: st stephens	-1.810*** (-2.639, -0.980)					
	Facility: vinod karhana	-1.959*** (-2.790, -1.128)					
	Diag Qtr: 2020 Q1	-0.516 (-1.209, 0.177)					
	Facility: st stephens * Diag Qtr 2020 Q1	0.475 (-0.528, 1.478)					
	Facility: vinod karhana * Diag Qtr 2020 Q1	1.152 (-0.002, 2.306)					
	Constant	3.063** (0.818, 5.307)					
	Observations	946					
	Log Likelihood	-288.016					
	Akaike Inf. Crit.	608.032					

Note: a) 95% C.I. based on robust standard errors; b) *p<0.1; **p<0.05; ***p<0.01; c) Model was fitted on

the matched dataset

509

510 Appendix 6 – Sensitivity Analysis; Results from Simple OLS & Logistic Models; Matched and

511 Unmatched (observational) datasets

512

513 Table S9

514 Sensitivity analysis for OLS regression modelling the impact of CfL engagement on number of follow-ups

		95% C.I.		Number of
	Coefficient			observations
Observational	6.423***	5.32	7.525	774
Matched	6.417***	5.295	7.54	745
Matched; alternative	5.757***	4.359	7.155	333
Sir Ganga Ram (only)	5.083***	3.291	6.876	377
St Stephens (only)	7.297***	5.255	9.338	203
Vinod Karhana (only)	6.434***	4.48	8.389	165
Observational; removed LTFU	6.001***	4.89	7.111	747
Matched; removed LTFU	6.003***	4.874	7.132	719
Matched; alternative; removed LTFU	5.329***	3.922	6.736	319

Note: a) All models control for all potential confounders; b) 95% C.I. based on robust standard errors; c) LTFU refers to patient who were lost to follow-up, d) All facility wise models are fitted on the matched dataset; e) Matched (alternative) refers to a matched dataset which was created by matching using a combination of nearest neighbor (age, free drugs, facility, diagnosing quarter) and exact matching (Xpert testing, gender, extra pulmonary status) methods; f) *p<0.1; **p<0.05; ***p<0.01

515

516

517 Table S10

518 Sensitivity analysis for logistic regression, modelling the impact of the CfL engagement on treatment outcomes

519

	Odds Batio (OB)	95% C.I. (OR)		Number of
				observations
Observational	1.255***	1.788	6.888	989
Matched	1.228***	1.701	6.857	944
Matched; alternative	1.181***	1.563	6.791	408
Sir Ganga Ram (only)	0.425	0.349	6.702	519
St Stephens (only)	1.250***	1.405	8.677	256
Vinod Karhana (only)	1.562***	1.145	19.856	169
Observational; removed LTFU	1.319***	1.687	8.294	962
Matched; removed LTFU	1.319***	1.626	8.606	918
Matched; alternative; removed LTFU	1.229***	1.391	8.405	394

Note: a) All models control for all potential confounders; b) 95% C.I. based on robust standard errors; c) LTFU refers to patient who were lost to follow-up, d) All facility wise models are fitted on the matched dataset; e) Matched (alternative) refers to a matched dataset which was created by matching using a combination of nearest neighbor (age, free drugs, facility, diagnosing quarter) and exact matching (Xpert testing, gender, extra pulmonary status) methods; f) *p<0.1; **p<0.05; ***p<0.01

520 Appendix 7 – Alternative Matching method

521 Multiple different matching specifications were run to test for the robustness of the model. We report results 522 for one such alternative matching specification. In this alternative specification, we used the nearest neighbor 523 algorithm to match four covariates, 1) age category, 2) free drug status, 3) facility of diagnosis and 4) diagnosing 524 quarter, and exact matching for 1) proportion of males, 2) proportion of extra pulmonary cases, and 3)

- 525 proportion of patients diagnosed using Xpert testing. The caliper width used was 0.2. This particular matching
- 526 resulted in 204 pairs (408 observations), relative to 944 observations obtained by way of full matching. The
- matching resulted in a more similar set of covariates for the two groups, as observed by the p-values obtained 527
- 528 for testing difference between two groups (Table S11).
- 529

530 Table S11

531 Comparison of descriptive statistics between matched datasets (full matching vs nearest neighbor)

	Matched (Full)			Matched (Nearest Neighbor)		
	(N = 944)			(N = 408)		
Pilot engagement	no CfL	CfL	p- value	no CfL	CfL	p- value
Number of patients	694	250		694	250	
Males	398 (57%)	132 (53%)	0.2	109 (53%)	109 (53%)	>0.9
Age Category						0.3
1.0-5	6 (0.9%)	3 (1.2%)		2 (1.0%)	3 (1.5%)	
2. 6-15	45 (6.5%)	20 (8.0%)		12 (5.9%)	15 (7.4%)	
3. 16-19	51 (7.3%)	34 (14%)		19 (9.3%)	32 (16%)	
4. 20-45	334 (48%)	143 (57%)		121 (59%)	106 (52%)	
5. 46-65	186 (27%)	40 (16%)		35 (17%)	38 (19%)	
6. >65	72 (10%)	10 (4.0%)		15 (7.4%)	10 (4.9%)	0.2
Age	37 (24, 56)	30 (20, 42)	<0.001	29 (22, 45)	29 (20, 45)	>0.9
Free drugs	41 (5.9%)	50 (20%)	<0.001	39 (19%)	40 (20%)	>0.9
Xpert Testing	88 (13%)	97 (39%)	<0.001	70 (34%)	70 (34%)	>0.9
Extra Pulmonary	402 (58%)	126 (50%)	0.040	101 (50%)	101 (50%)	<0.001
Follow Ups	11 (4, 16)	18 (13, 20)	<0.001	12 (4, 17)	18 (13, 21)	
Unknown	173	26		53	22	0.9
Facility			<0.001			
sir ganga ram	447 (64%)	72 (29%)		62 (30%)	64 (31%)	
st stephens	143 (21%)	113 (45%)		84 (41%)	87 (43%)	
vinod karhana	104 (15%)	65 (26%)		58 (28%)	53 (26%)	
Successful treatment outcome	595 (86%)	237 (95%)	<0.001	170 (83%)	192 (94%)	<0.001

Notes: 1) The	table showcases the numbers segregated by CfL status, and within group percentages for
them; 2) For	binary/character variables, values represent the number of patients enrolled, and value in
parentheses	represents share or %; 3) For continuous values, the number represents the median, and the
values in par	entheses represents the Interquartile Range; 4) Pearson's Chi-squared test and Kruskal-Wallis
rank sum tes	t is conducted for p value

537 **References**

532

533

534

535

536

- 538 [1] B. K. Ngwatu *et al.*, "The impact of digital health technologies on tuberculosis
- treatment: a systematic review," *Eur. Respir. J.*, vol. 51, no. 1, p. 1701596, Jan. 2018, doi:
- 540 10.1183/13993003.01596-2017.

541 [2] A. Ridho et al., "Digital Health Technologies to Improve Medication Adherence and

542 Treatment Outcomes in Patients With Tuberculosis: Systematic Review of Randomized

543 Controlled Trials," J. Med. Internet Res., vol. 24, no. 2, p. e33062, Feb. 2022, doi:

544 10.2196/33062.

545 [3] R. Subbaraman *et al.*, "Digital adherence technologies for the management of

tuberculosis therapy: mapping the landscape and research priorities," *BMJ Glob. Health*, vol.

547 3, no. 5, p. e001018, Oct. 2018, doi: 10.1136/bmjgh-2018-001018.

548 [4] S. Kumar et al., "Mobile Health Technology Evaluation," Am. J. Prev. Med., vol. 45,

- no. 2, pp. 228–236, Aug. 2013, doi: 10.1016/j.amepre.2013.03.017.
- 550 [5] D. C. Mohr, K. Cheung, S. M. Schueller, C. Hendricks Brown, and N. Duan,
- 551 "Continuous Evaluation of Evolving Behavioral Intervention Technologies," Am. J. Prev.
- 552 *Med.*, vol. 45, no. 4, pp. 517–523, Oct. 2013, doi: 10.1016/j.amepre.2013.06.006.
- 553 [6] M. S. Marcolino, J. A. Q. Oliveira, M. D'Agostino, A. L. Ribeiro, M. B. M. Alkmim,
- and D. Novillo-Ortiz, "The Impact of mHealth Interventions: Systematic Review of

- 555 Systematic Reviews," *JMIR MHealth UHealth*, vol. 6, no. 1, p. e23, Jan. 2018, doi:
- 556 10.2196/mhealth.8873.
- 557 [7] J. Needamangalam Balaji *et al.*, "A Scoping Review on Accentuating the Pragmatism
- in the Implication of Mobile Health (mHealth) Technology for Tuberculosis Management in
- 559 India," J. Pers. Med., vol. 12, no. 10, p. 1599, Sep. 2022, doi: 10.3390/jpm12101599.
- 560 [8] C. M. Denkinger, J. Grenier, A. K. Stratis, A. Akkihal, N. Pant-Pai, and M. Pai,
- ⁵⁶¹ "Mobile health to improve tuberculosis care and control: a call worth making [Review
- s62 article]," Int. J. Tuberc. Lung Dis., vol. 17, no. 6, pp. 719–727, Jun. 2013, doi:
- 563 10.5588/ijtld.12.0638.
- 564 [9] W. Tumuhimbise and A. Musiimenta, "A review of mobile health interventions for
- public private mix in tuberculosis care," *Internet Interv.*, vol. 25, p. 100417, Sep. 2021, doi:
- 566 10.1016/j.invent.2021.100417.
- 567 [10] "Joint Effort for Elimination of Tuberculosis." Accessed: Jun. 28, 2022. [Online].
 568 Available: https://www.projectjeet.in/
- 569 [11] "Connect for LifeTM (powered by Johnson & Johnson Global Public Health);
- 570 https://wiki.openmrs.org/display/docs/Connect+for+Life+Distribution."
- 571 [12] Central TB Division, "Treatment Outcomes for drug susceptible TB patients," in
- 572 Technical and Operational Guidelines for TB Control in India, 2016, p. 65. [Online].
- 573 Available: https://tbcindia.gov.in/showfile.php?lid=3220
- 574 [13] C. G. Victora, J.-P. Habicht, and J. Bryce, "Evidence-Based Public Health: Moving
- 575 Beyond Randomized Trials," *Am J Public Health*, vol. 94, pp. 400–5, 2004.
- 576 [14] M. S. Ali, D. Prieto-Alhambra, L. C. Lopes, D. Ramos, N. Bispo, and M. Y. Ichihara,
- ⁵⁷⁷ "Propensity Score Methods in Health Technology Assessment: Principles, Extended
- Applications, and Recent Advances," *Front Pharmacol*, vol. 10, no. 973, 2019.
- 579 [15] A. Cois and R. Ehrlich, "Problem drinking as a risk factor for tuberculosis: a
- propensity score matched analysis of a national survey," *BMC Public Health*, vol. 13, no.
- 581 871, 2013.

- 582 [16] P. C. Austin, "An Introduction to Propensity Score Methods for Reducing the Effects
- of Confounding in Observational Studies," *Multivar. Behav Res*, vol. 46, pp. 399–424, 2011.
- 584 [17] M. Caliendo and S. Kopeinig, "Some Practical Guidance for the Implementation of
- 585 Propensity Score Matching," *J Econ. Surv.*, vol. 22, pp. 31–72, 2008.
- 586 [18] P. R. Rosenbaum and D. B. Rubin, "The central role of the propensity score in
- observational studies for causal effects," *Biometrika*, vol. 70, no. 1, pp. 41–55, 1983, doi:
- 588 10.1093/biomet/70.1.41.
- 589 [19] W. C. Winkelmayer and T. Kurth, "Propensity scores: help or hype?," Nephrol. Dial.
- 590 Transplant., vol. 19, no. 7, pp. 1671–1673, Jul. 2004, doi: 10.1093/ndt/gfh104.
- 591 [20] C. Heinrich, A. Maffioli, and G. Vázquez, "A Primer for Applying Propensity-Score
- 592 Matching," Inter-American Development Bank, Office of Strategic Planning and
- 593 Development Effectiveness (SPD), SPD Working Paper 1005, Aug. 2010. Accessed: Aug.
- 12, 2022. [Online]. Available: https://econpapers.repec.org/paper/idbspdwps/1005.htm
- 595 [21] P. R. Rosenbaum, "A Characterization of Optimal Designs for Observational
- 596 Studies," J. R. Stat. Soc. Ser. B Methodol., vol. 53, no. 3, pp. 597–610, 1991, doi:
- 597 http://www.jstor.org/stable/2345589.
- 598 [22] B. B. Hansen, "Full Matching in an Observational Study of Coaching for the SAT," J.
- 599 Am. Stat. Assoc., vol. 99, no. 467, pp. 609–618, Sep. 2004, doi:
- 600 10.1198/01621450400000647.
- 601 [23] K. Ming and P. R. Rosenbaum, "Substantial Gains in Bias Reduction from Matching
- with a Variable Number of Controls," *Biometrics*, vol. 56, no. 1, pp. 118–124, Mar. 2000,
- 603 doi: 10.1111/j.0006-341X.2000.00118.x.
- 604 [24] P. C. Austin, "Optimal caliper widths for propensity-score matching when estimating
- differences in means and differences in proportions in observational studies," *Pharm Stat*,
- 606 vol. 10, pp. 150–61, 2011.
- 607 [25] H. O. Balli and B. E. Sørensen, "Interaction effects in econometrics," Empir. Econ.,
- vol. 45, no. 1, pp. 583–603, Aug. 2013, doi: 10.1007/s00181-012-0604-2.

- 609 [26] Q.-Y. Zhao, J.-C. Luo, Y. Su, Y.-J. Zhang, G.-W. Tu, and Z. Luo, "Propensity score
- 610 matching with R: conventional methods and new features," *Ann. Transl. Med.*, vol. 9, pp.
- 611 812-812, 2021.
- 612 [27] D. Ho, K. Imai, G. King, and S. E. A. MatchIt, "Nonparametric Preprocessing for
- Parametric Causal Inference," J. Stat. Softw., vol. 42, pp. 1–28, 2011.
- 614 [28] S. Selvaraj, K. Karan, S. Srivastava, N. Bhan, and I. Mukhopadhyay, "India Health
- 615 System Review." World Health Organization, Regional Office for South-East Asia, 2022.
- 616 [Online]. Available: https://apo.who.int/publications/i/item/india-health-system-review
- 617 [29] R. Danasekaran, T. Raja, and B. Kumar M, "mHealth: A Newer Perspective in
- Healthcare through Mobile Technology," J. Compr. Health, vol. 7, no. 2, pp. 67–68, Dec.
- 619 2019, doi: 10.53553/JCH.v07i02.012.
- [30] A. Musiimenta *et al.*, "Mobile Health Technologies May Be Acceptable Tools for
- 621 Providing Social Support to Tuberculosis Patients in Rural Uganda: A Parallel Mixed-
- 622 Method Study," *Tuberc. Res. Treat.*, vol. 2020, pp. 1–8, Jan. 2020, doi:
- 623 10.1155/2020/7401045.
- [31] I. Margineanu et al., "Patients and Medical Staff Attitudes Toward the Future
- 625 Inclusion of eHealth in Tuberculosis Management: Perspectives From Six Countries
- Evaluated using a Qualitative Framework," JMIR MHealth UHealth, vol. 8, no. 11, p.
- e18156, Nov. 2020, doi: 10.2196/18156.
- 628 [32] A. I. Latif, E. L. Sjattar, and K. A. Erika, "Models and benefits of mobile health
- application to support patient with tuberculosis: A literature review," *Enferm. Clínica*, vol.
- 630 30, pp. 163–167, Mar. 2020, doi: 10.1016/j.enfcli.2019.07.069.
- [33] N. Arinaminpathy *et al.*, "Modelling the potential impact of adherence technologies
- on tuberculosis in India," Int. J. Tuberc. Lung Dis., vol. 24, no. 5, pp. 526–533, May 2020,
- 633 doi: 10.5588/ijtld.19.0472.

- 634 [34] S. B. Nagaraja *et al.*, "Kill-TB' Drug Reminder Mobile Application for Tuberculosis
- Patients at Bengaluru, India: Effectiveness and Challenges," J. Tuberc. Res., vol. 08, no. 01,
- 636 pp. 1–10, 2020, doi: 10.4236/jtr.2020.81001.
- 637 [35] S. Oberoi, V. K. Gupta, N. Chaudhary, and A. Singh, "99 DOTS Mini Review,"
- 638 *ICJMR*, 2016, [Online]. Available:
- https://www.researchgate.net/publication/315542622 99 DOTS MINI-REVIEW
- [36] World Health Organization, Handbook for the use of digital technologies to support
- 641 *tuberculosis medication adherence*. Geneva: World Health Organization, 2017. Accessed:
- Feb. 01, 2023. [Online]. Available: https://apps.who.int/iris/handle/10665/259832
- [37] X. Liu *et al.*, "Usability of a Medication Event Reminder Monitor System (MERM)
- by Providers and Patients to Improve Adherence in the Management of Tuberculosis," Int. J.
- 645 Environ. Res. Public. Health, vol. 14, no. 10, p. 1115, Sep. 2017, doi:
- 646 10.3390/ijerph14101115.
- 647 [38] S. Saha *et al.*, "Tuberculosis Monitoring Encouragement Adherence Drive (TMEAD):
- Toward improving the adherence of the patients with drug-sensitive tuberculosis in Nashik,
- 649 Maharashtra," Front. Public Health, vol. 10, p. 1021427, Dec. 2022, doi:
- 650 10.3389/fpubh.2022.1021427.
- [39] B. E. Thomas *et al.*, "Acceptability of the Medication Event Reminder Monitor for
- Promoting Adherence to Multidrug-Resistant Tuberculosis Therapy in Two Indian Cities:
- 653 Qualitative Study of Patients and Health Care Providers," J. Med. Internet Res., vol. 23, no.
- 654 6, p. e23294, Jun. 2021, doi: 10.2196/23294.
- 655 [40] T. Manyazewal, Y. Woldeamanuel, D. P. Holland, A. Fekadu, and V. C. Marconi,
- ⁶⁵⁶ "Effectiveness of a digital medication event reminder and monitor device for patients with
- tuberculosis (SELFTB): a multicenter randomized controlled trial," *BMC Med.*, vol. 20, no.
- 658 1, p. 310, Sep. 2022, doi: 10.1186/s12916-022-02521-y.
- 659 [41] D. Drabarek, N. T. Anh, N. V. Nhung, N. B. Hoa, G. J. Fox, and S. Bernays,
- 660 "Implementation of Medication Event Reminder Monitors among patients diagnosed with

- drug susceptible tuberculosis in rural Viet Nam: A qualitative study," *PLOS ONE*, vol. 14,
- no. 7, p. e0219891, Jul. 2019, doi: 10.1371/journal.pone.0219891.
- [42] J. Acosta, P. Flores, M. Alarcón, M. Grande-Ortiz, L. Moreno-Exebio, and Z. M.
- 664 Puyen, "A randomised controlled trial to evaluate a medication monitoring system for TB
- 665 treatment," Int. J. Tuberc. Lung Dis., vol. 26, no. 1, pp. 44–49, Jan. 2022, doi:
- 666 10.5588/ijtld.21.0373.
- 667 [43] A. Cross *et al.*, "99DOTS: a low-cost approach to monitoring and improving
- 668 medication adherence," in Proceedings of the Tenth International Conference on Information
- and Communication Technologies and Development, Ahmedabad India: ACM, Jan. 2019, pp.
- 670 1–12. doi: 10.1145/3287098.3287102.
- 671 [44] D. Thakkar, K. Piparva, and S. Lakkad, "A pilot project: 99DOTS information
- 672 communication technology-based approach for tuberculosis treatment in Rajkot district,"
- *Lung India*, vol. 36, no. 2, p. 108, 2019, doi: 10.4103/lungindia.lungindia_86_18.
- [45] N. Alipanah *et al.*, "Adherence interventions and outcomes of tuberculosis treatment:
- A systematic review and meta-analysis of trials and observational studies," *PLOS Med.*, vol.
- 676 15, no. 7, p. e1002595, Jul. 2018, doi: 10.1371/journal.pmed.1002595.
- [46] X. Liu et al., "Effectiveness of Electronic Reminders to Improve Medication
- Adherence in Tuberculosis Patients: A Cluster-Randomised Trial," PLOS Med., vol. 12, no.
- 679 9, p. e1001876, Sep. 2015, doi: 10.1371/journal.pmed.1001876.
- 680 [47] P. Thekkur *et al.*, "Outcomes and implementation challenges of using daily treatment
- regimens with an innovative adherence support tool among HIV-infected tuberculosis
- patients in Karnataka, India: a mixed-methods study," *Glob. Health Action*, vol. 12, no. 1, p.
- 683 1568826, Jan. 2019, doi: 10.1080/16549716.2019.1568826.
- [48] N. K. Jose, C. Vaz, P. R. Chai, and R. Rodrigues, "The Acceptability of Adherence
- 685 Support via Mobile Phones for Antituberculosis Treatment in South India: Exploratory
- 686 Study," JMIR Form. Res., vol. 6, no. 5, p. e37124, May 2022, doi: 10.2196/37124.

- 687 [49] R. Sodhi, M. J. Penkunas, and A. Pal, "Free drug provision for tuberculosis increases
- patient follow-ups and successful treatment outcomes in the Indian private sector: A quasi
- experimental study using propensity score matching," In Review, preprint, Jan. 2023. doi:
- 690 10.21203/rs.3.rs-2448126/v1.
- [50] Z. Shubber *et al.*, "Patient-Reported Barriers to Adherence to Antiretroviral Therapy:
- A Systematic Review and Meta-Analysis," *PLOS Med.*, vol. 13, no. 11, p. e1002183, Nov.
- 693 2016, doi: 10.1371/journal.pmed.1002183.
- [51] S. A. Munro, S. A. Lewin, H. J. Smith, M. E. Engel, A. Fretheim, and J. Volmink,
- 695 "Patient Adherence to Tuberculosis Treatment: A Systematic Review of Qualitative
- 696 Research," *PLoS Med.*, vol. 4, no. 7, p. e238, Jul. 2007, doi: 10.1371/journal.pmed.0040238.
- 697 [52] S. J. Iribarren, R. Schnall, P. W. Stone, and A. Carballo-Diéguez, "Smartphone
- 698 Applications to Support Tuberculosis Prevention and Treatment: Review and Evaluation,"
- *JMIR MHealth UHealth*, vol. 4, no. 2, p. e25, May 2016, doi: 10.2196/mhealth.5022.
- 700 [53] D. J Carter *et al.*, "The impact of a cash transfer programme on tuberculosis treatment
- success rate: a quasi-experimental study in Brazil," *BMJ Glob. Health*, vol. 4, no. 1, p.
- roz e001029, Jan. 2019, doi: 10.1136/bmjgh-2018-001029.
- 703 [54] D. L. Sackett, Ed., Evidence-based medicine: how to practice and teach EBM, 2nd
- ed., Reprinted. Edinburgh: Churchill Livingstone, 2001.